Background: Nicotine use is a major modifiable risk factor for acute myocardial infarction (AMI), yet national mortality patterns involving co‐listed nicotine dependence remain under‐characterized. Methods: Using CDC WONDER Multiple Cause of Death data from 1999 to 2020, we evaluated AMI‐related mortality among US adults aged ≥ 25 years with co‐listed death‐certificate‐coded nicotine dependence, operationally defined using ICD‐10 F17.0–F17.9. AMI was identified using ICD‐10 I21.0–I22.9. Age‐adjusted mortality rates (AAMRs) per 100 000 population were calculated using the 2000 US standard population. Temporal trends were assessed using Joinpoint regression and stratified by sex, age, race/ethnicity, region, urbanization, state, and place of death. Results: From 1999 to 2020, 357 167 AMI‐related deaths with co‐listed nicotine dependence occurred among adults aged ≥ 25 years. The AAMR increased from 1.64 to 9.46 per 100 000 population (average annual percent change, 10.27%; p < 0.001). Men had higher AAMRs than women (11.30 vs. 4.27), with significant increases in both groups. Mortality increased with age, highest among adults aged ≥ 85 years (33.55) and lowest among those aged 35–44 years (0.83). Non‐Hispanic American Indian/Alaska Native adults had the highest AAMR (10.30). Rates were higher in the Midwest and South, nonmetropolitan areas exceeded metropolitan areas, and the highest state‐level AAMRs occurred in North Dakota and Wyoming. Most deaths occurred in inpatient facilities or at home. Conclusion: AMI‐related mortality with co‐listed nicotine dependence increased substantially from 1999 to 2020, with persistent demographic and geographic disparities. These findings may inform targeted tobacco‐control, nicotine‐cessation, and cardiovascular prevention strategies for high‐risk populations over time.
Introduction: Coronary artery disease (CAD) remains a leading cause of mortality, and hypertension serves as a primary, modifiable risk factor. While cardiovascular mortality historically declined, recent data indicate this trajectory has plateaued and begun to reverse. This study analyzes the temporal trends and demographic disparities in mortality due to CAD and hypertension among adults in the United States. Methods: This retrospective study utilized the CDC WONDER database to extract mortality data from 2000 to 2024. Deaths among adults aged 25 years and older with CAD and hypertension were identified. Age‐adjusted mortality rates (AAMRs) per 100 000 population were calculated. Temporal patterns and annual percent change (APC) were evaluated using Joinpoint regression analysis. Results: Between 2000 and 2024, 3 776 396 deaths occurred due to CAD and hypertension among US adults. Overall AAMR rose from 57.22 to 76.95, driven by a steep 2018–2021 increase (APC: 10.13%) before a recent decline (2021–2024, APC: −3.50%). By 2024, male AAMR (106.43) doubled female AAMR (52.68). Non‐Hispanic African American adults experienced the highest AAMR (96.90). Non‐metropolitan areas saw greater sustained increases (AAPC: 2.79%) than metropolitan areas (AAPC: 1.23%), with the South recording the highest regional AAMR (70.25; AAPC: 1.53%). While essential hypertension mortality stabilized, hypertensive heart disease (AAPC: 4.35%) and renal disease (AAPC: 8.83%) surged. Chronic ischemic heart disease remained the leading CAD subtype (AAPC: 1.37%). Conclusion: CAD and hypertension‐related mortality among adults has increased significantly over the past 25 years, exposing significant demographic disparities. Targeted public health strategies prioritizing optimal blood pressure management and equitable healthcare access are essential to mitigate this escalating burden.